Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer

被引：5
作者：
Bennouna, Jaafar [1 ]
机构：
[1] Univ Hosp Nantes, Dept Pneumol, Thorac Oncol, Nantes, France
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 21期
关键词：
afatinib; combination; EGFR; non-small-cell lung cancer; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; DUAL INHIBITION; GEFITINIB; CHEMOTHERAPY; NSCLC; CETUXIMAB; BIBW2992;
D O I：
10.2217/fon-2017-0240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1829 / 1833
页数：5
相关论文
共 26 条
[1]   EGFR TKI combination with immunotherapy in non-small cell lung cancer [J].
Ahn, Myung-Ju ;
Sun, Jong-Mu ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil .
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) :465-469
[2]   Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress [J].
Bennouna, Jaafar ;
Vera, Shanti Ricardo Moreno .
FUTURE ONCOLOGY, 2016, 12 (03) :355-372
[3]   Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies [J].
Brahmkhatri, Varsha P. ;
Prasanna, Chinmayi ;
Atreya, Hanudatta S. .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[4]   Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].
Chen, Nan ;
Fang, Wenfeng ;
Zhan, Jianhua ;
Hong, Shaodong ;
Tang, Yanna ;
Kang, Shiyang ;
Zhang, Yaxiong ;
He, Xiaobo ;
Zhou, Ting ;
Qin, Tao ;
Huang, Yan ;
Yi, Xianping ;
Zhang, Li .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923
[5]   Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer [J].
Corallo, Salvatore ;
D'Argento, Ettore ;
Strippoli, Antonia ;
Basso, Michele ;
Monterisi, Santa ;
Rossi, Sabrina ;
Cassano, Alessandra ;
Barone, Carlo M. .
TARGETED ONCOLOGY, 2017, 12 (02) :153-161
[6]   Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance [J].
Denduluri, Sahitya K. ;
Idowu, Olumuyiwa ;
Wang, Zhongliang ;
Liao, Zhan ;
Yan, Zhengjian ;
Mohammed, Maryam K. ;
Ye, Jixing ;
Wei, Qiang ;
Wang, Jing ;
Zhao, Lianggong ;
Luu, Hue H. .
GENES & DISEASES, 2015, 2 (01) :13-25
[7]  
Gazzah A, 2016, EORTC NCI AACR MOL T
[8]   Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors [J].
Goldberg, Sarah B. ;
Oxnard, Geoffrey R. ;
Digumarthy, Subba ;
Muzikansky, Alona ;
Jackman, David M. ;
Lennes, Inga T. ;
Sequist, Lecia V. .
ONCOLOGIST, 2013, 18 (11) :1214-1220
[9]   Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer [J].
Hidaka, Noriko ;
Iwama, Eiji ;
Kubo, Naoki ;
Harada, Taishi ;
Miyawaki, Kohta ;
Tanaka, Kentaro ;
Okamoto, Isamu ;
Baba, Eishi ;
Akashi, Koichi ;
Sasaki, Hiroyuki ;
Nakanishi, Yoichi .
LUNG CANCER, 2017, 108 :75-82
[10]   AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].
Jaenne, Pasi A. ;
Yang, James Chih-Hsin ;
Kim, Dong-Wan ;
Planchard, David ;
Ohe, Yuichiro ;
Ramalingam, Suresh S. ;
Ahn, Myung-Ju ;
Kim, Sang-We ;
Su, Wu-Chou ;
Horn, Leora ;
Haggstrom, Daniel ;
Felip, Enriqueta ;
Kim, Joo-Hang ;
Frewer, Paul ;
Cantarini, Mireille ;
Brown, Kathryn H. ;
Dickinson, Paul A. ;
Ghiorghiu, Serban ;
Ranson, Malcolm .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699
123